China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Tesla Raises Cybertruck Prices by $5,000 in US 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Add as a preferred source on Google
CAMBRIDGE, Mass., April 26, 2018 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, May 3, 2018, at 5:00 p.m. ET to discuss a corporate update and results for the first quarter of 2018.
To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 6079429. A live webcast of the presentation will be available on the Investors & Media section of the Editas website.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Contacts
Media:
Cristi Barnett
(617) 401-0113
[email protected]
Investors:
Mark Mullikin
(617) 401-9083
[email protected]
